YouTube Facebook LinkedIn Google+ Twitter Xingrss  

CardioDx Wins Medicare OK of Molecular Test for Heart Disease


August 8, 2012 | CardioDx has spent three years marketing a new genetic test that can tell when a patient’s chest pain is a sign of serious heart disease. It has a long way to go before becoming part of mainstream medicine, but now the company has taken a big step ahead by persuading Medicare that its test is worth the money. The company is announcing today that Palmetto GBA, the national contractor for Medicare, has agreed to reimburse the company for its Corus CAD test. Xconomy
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.